Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer

Primary Sponsor

ANZUP

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre

Accrual Target

800

Final Accrual

802

Closing Date of Accrual

30 June 2018

Trial Contact

enzarad.study@sydney.edu.au

Related Post

24 June, 2025

TROG 2024 Annual Research Report highlights a year of achievements

LATEST NEWS: 24 JUNE 2025 The latest annual report

11 June, 2025

Trial Could Prove a Game-Changer for Treating High-Risk Skin Cancer

LATEST NEWS: 11 JUNE 2025 New findings from a